Many hospitals struggle to achieve optimal compliance with the Drug Supply Chain Security Act (DSCSA). The challenge to comply seems to come from an incomplete or inaccurate understanding of the regulations, which is understandable given the Act’s complexity. DSCSA was put in place to protect consumers from harmful[...]
ConsortiEX is proud to announce T3 verification, the newest feature to be added to our DSCSA Compliance as a Service (CaaS) module. The T3 Verification process gives pharmacies maximum visibility to all T3 transactions, both electronic and paper, received by their pharmacy.
The FDA recently issued a draft guidance regarding verification* systems in accordance with the Drug Supply Chain Security Act (DSCSA).
We want to thank everybody who came to visit our booth at this year’s ASHP Midyear Clinical Meeting & Exhibition. We always appreciate the opportunity to show off our products to the people who need them most.
Understanding the rules and regulations behind DSCSA Compliance can be a daunting task. As deadlines pass, the FDA regularly updates what it means to be compliant. ConsortiEX is proud to offer DSCSA Compliance as a Service (CaaS). Our CaaS module removes the burden of being compliant from the dispenser community with[...]
ConsortiEX is proudly attending ASHP Midyear. Stop by Booth 900 to see how our intuitive Pharmacy-Focused ERP solutions can enhance your patient safety, ensure quality control, and simplify compliance, first-hand and in-person. Our new InsightRX Passive Audit Monitoring hood will be on display.
Several key industry players have issued responses to the FDA in regard to the recent draft guidance on the use of Product Identifiers, and the policy on grandfathered product, in compliance with the Drug Supply Chain Security Act (DSCSA).
On Sep. 9, 2018, the FDA released a Final Guidance regarding the use of product identifiers on packages and homogenous cases of product as mentioned in the Drug Supply Chain Security Act (DSCSA).
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency. We recognize that in delivering on implementation commitments, we must balance the need to preserve[...]